Regeneron Could Have a Big Catalyst Coming in 2022

Submitted by admin on October 9, 2021 - 11:11pm

Source:

Motley Fool

News Tags:

Headline:

snippet:

Libtayo significantly reduced the risk of death for patients with recurrent or metastatic cervical cancer.
If the FDA approves Libtayo as a treatment for cervical cancer, Regeneron could see around $500 million in additional annual sales from the drug.
Regeneron and Sanofi expect to file with European Union regulators for Libtayo's approval in the cervical cancer indication by the end of this year.

Search form